Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure.
Johanna K FreundtGerrit FrommeyerTilmann SpiekerFabian WötzelJochen Schulze GrotthoffJörg StypmannGeorg HempelMichael SchäfersAndreas H JacobsLars EckardtPhilipp Sebastian LangePublished in: BMC pharmacology & toxicology (2019)
In a rabbit model of heart failure, Entinostat diminishes heart failure related prolongation of repolarization and partially restores KCNH2 and Cav1.3 expression. In addition, Entinostat exerts antifibrotic properties both in vitro and in vivo. Thus, Entinostat might be an interesting candidate for the pharmaceutical therapy of heart failure directed against structural and electrical remodeling.